Rectal Cancer in Patient with Chronic Lymphocytic Leukemia Association with Brucellosis: The First Case Report

Mehrdad Payandeh¹, Edris Sadeghi^{2, 3,} , Masoud Sadeghi^{2, 3} and Fariba Falsafi⁴

¹Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

³Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

⁴Department of Nursing, Borujerd Branch, Islamic Azad University, Borujerd, Iran

Cite this paper:
Mehrdad Payandeh, Edris Sadeghi, Masoud Sadeghi and Fariba Falsafi. Rectal Cancer in Patient with Chronic Lymphocytic Leukemia Association with Brucellosis: The First Case Report. American Journal of Cancer Prevention. 2015; 3(5):89-90. doi: 10.12691/ajcp-3-5-3

Abstract

Introduction: Colorectal cancer is the fourth most common cancer in men and the third most common in women. Brucella infections in immune compromised hosts (like CLL) are relatively rare. Herein, we reported first case report, a patient have been diagnosed as simultaneous CLL and brucellosis during his follow up that she indicated a subsequent neoplasm after CLL according to our knowledge. Case Report: A 77-year-old male, presented to his primary care provider with complaint of weakness and fatigue. After analysis with bone marrow aspiration and biopsy, there was heavy infiltration with well-differentiated small lymphocytes so we diagnosed CLL for her problems. Then he was treated with prednisolone and cyclophosphamide with allopurinol. During the treatment period (about one year after the first visit), the patient was suffering from brucellosis that treated with cotrimoxazole + rifampicin regimen. In the continued his treatment, he had been treated with danazol and then intravenous immunoglobulin for a few attack of severe pneumonia. Recently he suffer of complaint of hematochezia, then refer for rectosigmoidoscopy with rectal mass lesion. In pathology reported well differentiation rectum adenocarcinoma. He had chemo irradiation with capecitabine and then with adjuvant regimen of CAPOX (Xeloda with oxaliplatin). At now he is alive with classic follow up. Conclusion: In patients with CLL and brucellosis we suggest that treatment for infection and leukemia simultaneously and we have enough notice about the patient's conditions because it may be created second non hematological malignancy. These clinical procedures make life more for the patient.

Keywords:
Brucellosis CLL Hematochezia Rectal cancer

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Payandeh M, Sadeghi M, Sadeghi E, Gholami F. Analysis of KRAS, BRAF and NRAS in Patients with Colorectal Cancer: the First Report of Western Iran. American Journal of Cancer Prevention. 2015. 3 (1): 19-22.
[2]	Dennis RJ, Alberts JC. The implications of an incidental chronic lymphocytic leukaemia in a resection specimen for colorectaladenocarcinoma. World J Surg Oncol. 2007. 5: 126.
[3]	Kyo K, Sameshima S, Tanaka Y, Murayama K, Shimano S, Kojima M, et al. Rectal cancer associated with chronic lymphocytic leukemia.J Gastroenterol. 2004. 39 (5): 479-83.
[4]	Al-Anazi KA, Al-Jasser AM. Brucella bacteremia in patients with acute leukemia: a case series. J Med Case Rep. 2007. 1: 144.
[5]	Payandeh M, Sadeghi M, Sadeghi E. Cholorambucil versus Cholorambucil plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran. Iran J Cancer Prev. 2015. 8 (2): 94-9.
[6]	De Stefano A, Carlomagno C. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoc lonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol. 2014. 20 (29): 9732-43.
[7]	Hisada M, Biggar RJ, Greene MH, Fraumeni JF Jr, Travis LB. Solid tumours after chronic lymphocytic leukemia. Blood. 2001. 98 (6): 1979-81.
[8]	Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, et al, O'Brien S. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010. 115 (3): 489-95.
[9]	Gaertner WB, Kwaan MR, Madoff RD, Melton GB.. Rectal cancer: An evidence-based update for primary care providers. World J Gastroenterol. 2015. 21 (25): 7659-71.